WALTHAM, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro), today reported financial results for the quarter ended September 30, 2019. Third Quarter Financial...
WALTHAM, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro) today announced its schedule of scientific and educational programs focused on corneal cross-linking and...
WALTHAM, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro), today announced the inclusion of a wide array of Boost Epi-On cross-linking (CXL) presentations in the...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avedro, Inc. PR Newswire NEW YORK, Aug. 8, 2019 NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential...
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Avedro, Inc. has obtained a Fair Price in its sale to Glaukos Corporation PR Newswire MILWAUKEE, Aug. 7, 2019 MILWAUKEE, Aug. 7...
Updates Full Year 2019 Revenue Guidance Earnings Call and Webcast Previously Scheduled for Tomorrow, Thursday, August 8 Will Now Occur Today, Wednesday, August 7 at 4:30 p.m. ET as a joint call...
Adds Novel Bio-Activated Pharmaceuticals to Glaukos’ New Corneal Health Franchise Potential Revenue Synergies from Complementary Product Portfolios that Leverage Glaukos’ Commercial Scale...
WALTHAM, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), today announced that it will release financial results for the second quarter of 2019 after the close of...
WALTHAM, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), today announced the company will be participating in the upcoming Guggenheim MedTech Disruptors Summit in...
WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro) today reported financial results for the quarter ended March 31, 2019. Recent Highlights First quarter 2019...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.